- $1.87m
- -$1.27m
- $2.49m
GeoVax Labs Inc expected to post a loss of $5.56 a share - Earnings Preview
GeoVax Labs Inc expected to post a loss of $3.15 a share - Earnings Preview
Brief: Geovax Labs Inc Files For Mixed Shelf Of Up To $100 Million – SEC Filing
GeoVax Labs Inc reports results for the quarter ended in December - Earnings Summary
GeoVax Labs Inc expected to post a loss of $2.78 a share - Earnings Preview
Brief: Geovax Labs Receives Letter From Nasdaq Stating Co To Have Regained Compliance With Nasdaq Listing Requirements
Brief: GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
Brief: Geovax Expands Rights Under Nih Covid-19 License To Include Mpox And Smallpox
Brief: Geovax Labs- On December 6, Company Received A Notice From Nasdaq Stating Nasdaq Has Determined To Delist Co's Securities From Nasdaq Capital Market
Brief: Geovax Commences Site Expansion For Phase 2 Trial
Brief: Geovax Receives Notice Of Allowance For Marburg Vaccine Patent
U.S. STOCKS ON THE MOVE-GeoVax Labs, Levi Strauss, Eli Lilly
GeoVax rises after receiving US patent for HIV vaccine
Brief: Geovax Receives Notice Of Allowance For Hiv Vaccine Patent
Brief: Geovax Completes Enrollment Of Phase 2 Trial For Next-Generation COVID-19 Vaccine Booster
Brief: Geovax Receives Notice Of Allowance For Malaria Vaccine Patent
GeoVax Labs Inc reports results for the quarter ended in June - Earnings Summary
GeoVax Labs Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Geovax To Report Q2 2023 Financial Results, Provide Corporate Update On August 9, 2023